Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP)

Atopic Dermatitis

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

Br J Dermatol

Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, Williams HC, Schmitt J, Gabes M, Howells L, Stuart BL, Grinich E, Pawlitschek T, Burton T, Howie L, Gadkari A, Eckert L, Ebata T, Boers M, Saeki H, Nakahara T, Katoh N

doi: 10.1111/bjd.19751

AcneAtopic Dermatitis

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Lancet

Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Kato N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD

doi: 10.1016/S0140-6736(21)00588-2

Atopic Dermatitis

The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

J Am Acad Dermatol.

Simpson E, Bissonnette R, Eichenfield LF, Guttman E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes F, Paller AS

doi: 10.1016/j.jaad.2020.04.104.

Atopic Dermatitis

Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study

J Am Acad Dermatol.

Fishbein AB, Mueller K, Kruse L, Boor P, Sheldon S, Zee P, Paller AS

doi: 10.1016/j.jaad.2017.08.043.

Atopic Dermatitis

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

Br J Dermatol.

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B

doi: 10.1111/bjd.16156.

Atopic Dermatitis

Texting atopic dermatitis patients to optimize learning and eczema area and severity index scores: A pilot randomized control trial

Pediatr Dermatol.

Singer HM, Levin LE, Morel KD, Garzon MC, Stockwell MS, Lauren CT

doi: 10.1111/pde.13510.

Atopic Dermatitis

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis

JAMA Dermatol.

Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A

doi: 10.1001/jamadermatol.2018.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema

Br J Dermatol.

Bosma AL, Spuls PI, Garcia-Doval I, Naldi L, Prieto-Merino D, Tesch F, Apfelbacher CJ, Arents BWM, Barbarot S, Baselga E, Deleuran M, Eichenfield LF, Gerbens LAA, Irvine AD, Manca A, Mendes-Bastos P, Middelkamp-Hup MA, Roberts A, Seneschal J, Svensson Å, Thyssen JP, Torres T, Vermeulen FM, Vestergaard C, von Kobyletzki LB, Wall D, Weidinger S, Schmitt J, Flohr C

doi: 10.1111/bjd.18452.

Atopic Dermatitis

Sensitivity of Clinician-Assessed Efficacy Outcome Measurement Instruments in Trials of Topical Therapies for Atopic Dermatitis: A Systematic Review and Meta-Analysis

J Eur Acad Dermatol Venereol

Légaré S, Chagnon M, Palijan A, Kojok K, Bissonnette R

doi: 10.1111/jdv.17743

Related content

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

Texting atopic dermatitis patients to optimize learning and eczema area and severity index scores: A pilot randomized control trial

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema

Sensitivity of Clinician-Assessed Efficacy Outcome Measurement Instruments in Trials of Topical Therapies for Atopic Dermatitis: A Systematic Review and Meta-Analysis